An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer

阿替唑单抗 医学 贝伐单抗 内科学 肿瘤科 结直肠癌 人口 临床终点 基因签名 奥沙利铂 癌症 彭布罗利珠单抗 随机对照试验 化疗 免疫疗法 生物 生物化学 基因表达 环境卫生 基因
作者
Carlotta Antoniotti,Alessandra Boccaccino,Robert S. Seitz,Mirella Giordano,Aurélie Catteau,Daniele Rossini,Filippo Pietrantonio,Lisa Salvatore,Kimberly McGregor,Francesca Bergamo,Veronica Conca,Simone Leonetti,Federica Morano,Giorgio Papiani,Emiliano Tamburini,Maria Bensi,Sabina Murgioni,Douglas Teller Ross,Alessandro Passardi,Isabelle Boquet
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:29 (12): 2291-2298 被引量:20
标识
DOI:10.1158/1078-0432.ccr-22-3878
摘要

PURPOSE: AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of patients with metastatic colorectal cancer (mCRC), with a modest benefit among proficient mismatch repair (pMMR). DetermaIO is an immune-related 27-gene expression signature able to predict benefit from immune checkpoint inhibition in triple-negative breast cancer. In this analysis of AtezoTRIBE, we investigated the predictive impact of DetermaIO in mCRC. EXPERIMENTAL DESIGN: Patients with mCRC unselected for MMR status were randomly assigned (1:2) to FOLFOXIRI plus bevacizumab (control arm) or the same regimen with atezolizumab (atezolizumab arm). qRT-PCR by DetermaIO was performed on RNA purified from pretreatment tumors of 132 (61%) of 218 enrolled patients. A binary result (IOpos vs. IOneg) adopting the preestablished DetermaIO cut-off point (0.09) was obtained, and an exploratory optimized cut-off point (IOOPT) was computed in the overall population and in pMMR subgroup (IOOPTpos vs. IOOPTneg). RESULTS: DetermaIO was successfully determined in 122 (92%) cases, and 23 (27%) tumors were IOpos. IOpos tumors achieved higher PFS benefit from atezolizumab arm than IOneg (HR: 0.39 vs. 0.83; Pinteraction = 0.066). In pMMR tumors (N = 110), a similar trend was observed (HR: 0.47 vs. 0.93; Pinteraction = 0.139). In the overall population, with the computed IOOPT cut-off point (0.277), 16 (13%) tumors were IOOPTpos and they derived higher PFS benefit from atezolizumab than IOOPTneg (HR: 0.10 vs. 0.85, Pinteraction = 0.004). Similar results were found in the pMMR subgroup. CONCLUSIONS: DetermaIO may be useful to predict benefit of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in mCRC. The exploratory IOOPT cut-off point should be validated in independent mCRC cohorts.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
高挑的葵阴完成签到,获得积分10
刚刚
刚刚
vivvy完成签到,获得积分10
刚刚
Micalblame完成签到,获得积分10
1秒前
1秒前
田瑜完成签到,获得积分10
1秒前
将个烂就完成签到,获得积分10
1秒前
愉快的友绿完成签到 ,获得积分10
1秒前
奥丁蒂法完成签到,获得积分10
2秒前
PSQ完成签到,获得积分10
2秒前
fannyeast完成签到,获得积分10
2秒前
大柚大利完成签到,获得积分10
2秒前
纪秋完成签到,获得积分10
2秒前
siraotianya发布了新的文献求助10
3秒前
独特乘风完成签到,获得积分10
3秒前
WANGL完成签到 ,获得积分10
3秒前
Chen完成签到,获得积分10
3秒前
佳思思完成签到,获得积分10
3秒前
CipherSage的应助被sssyz采纳,获得10
3秒前
十七完成签到 ,获得积分20
3秒前
深情冬云完成签到,获得积分10
3秒前
DengYue完成签到,获得积分10
3秒前
王大可完成签到,获得积分10
3秒前
kenneth完成签到,获得积分10
3秒前
gxmu6322完成签到,获得积分10
4秒前
4秒前
Ava的应助被科研通管家采纳,获得10
4秒前
专注的海燕完成签到,获得积分10
4秒前
小蘑菇的应助被科研通管家采纳,获得10
4秒前
聪明的归尘完成签到,获得积分10
4秒前
SAKURA的应助被科研通管家采纳,获得10
4秒前
hugfan完成签到,获得积分10
4秒前
dagongren完成签到,获得积分10
4秒前
张大仙完成签到,获得积分10
4秒前
隐形曼青的应助被科研通管家采纳,获得10
4秒前
天际小山完成签到,获得积分10
4秒前
小马甲的应助被科研通管家采纳,获得10
5秒前
科目三的应助被科研通管家采纳,获得10
5秒前
彳亍发布了新的文献求助30
5秒前
田様的应助被科研通管家采纳,获得10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180275
求助须知:如何正确求助?哪些是违规求助? 9570366
关于积分的说明 21810725
捐赠科研通 7776380
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479042